SAN DIEGO, Sept. 19, 2017 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted
oncology biotechnology company, will present at the 2017 Cantor
Fitzgerald Global Healthcare Conference in New York on Tuesday,
September 26th at 1:40
p.m. ET/ 10:40 a.m. PT. Mirati
will also participate in the Leerink Partners Roundtable Series –
Rare Disease & Immuno-Oncology Conference in New York on Thursday,
September 28th at 10:00
a.m. ET/ 7:00 a.m. PT.
Charles M. Baum, M.D., Ph.D.,
President and Chief Executive Officer will represent Mirati at both
conferences.
The conferences will be webcast and made available through the
"Investors" section of www.mirati.com, and replays will be made
available for 90 days following the events.
About Mirati Therapeutics
Mirati Therapeutics is a clinical-stage oncology company
developing targeted drugs to address the genetic, epigenetic and
immunological promoters of cancer. Our precision oncology clinical
programs utilize next-generation genomic testing to identify and
select cancer patients who are most likely to benefit from targeted
drug treatment. In immuno-oncology, we are advancing clinical
programs where the ability of our drugs to improve the immune
environment of tumor cells may enhance and expand the efficacy of
existing immunotherapy medicines when given in combination. Our
pre-clinical programs include potentially first-in-class and
best-in-class drugs specifically designed to address mutations and
tumors where few treatment options exist. We approach each of our
discovery and development programs with a singular focus: to
translate our deep understanding of the molecular drivers of cancer
into better drugs and better outcomes for patients. For more
information, visit www.mirati.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-upcoming-healthcare-conferences-300522331.html
SOURCE Mirati Therapeutics, Inc.